Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis
Phase I Open Label Dose-Escalation Study to Evaluate the Safety and Immunogenicity of H56:IC31 (AERAS-456) in HIV-negative Adults With and Without Latent Tuberculosis Infection
Sponsor: Aeras
A PHASE1 clinical study on Latent Tuberculosis and Latent Tuberculosis Bacteriology and Histology Unknown, this trial is completed. The trial is conducted by Aeras and has accumulated 7 data snapshots since 2011. Infectious disease trials contribute critical data for public health response and treatment development.
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Sep 2019 [monthly]
Completed PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Nov 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aeras
- Statens Serum Institut
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Worcester, South Africa